Shoppers are losing faith in faddy, miracle foods that promise much but deliver little, apart from lighter wallets. Consumers are choosing instead to eat more naturally healthy foods, new research indicates.
After years spent swallowing pledges from giant food manufacturers such as Unilever and Danone, consumers are mounting a pro-biotic backlash. The amount of money spent on "functional" yoghurt drinks promising anything from greater brains and beauty to lower your cholesterol and stomach gas fell last year.
To read more of this content at Newsvine, click here.
Showing posts with label functional foods. Show all posts
Showing posts with label functional foods. Show all posts
Saturday, April 19, 2008
Wednesday, March 26, 2008
Neutraceuticals Market Assessment 2008 Out Now
The nutraceuticals market comprises the combined functional foods and vitamins, minerals and supplements (VMS) sectors. The larger functional foods sector encompasses principally the four areas of: breakfast cereals fortified with fibre and sometimes with vitamins
and minerals; probiotic yoghurts and yoghurt drinks; cholesterol-lowering margarines; and soya milks. A newer and growing segment is fortified breads. Fortified breakfast cereals and probiotic yoghurts/yoghurt drinks are claimed to aid digestion, and cholesterol-lowering margarines are targeted at heart health. The use of the cholesterol-lowering active ingredients has been extended to probiotic yoghurts and yoghurt drinks, and to milk and cheese.
The smaller VMS sector is dominated by single and multivitamins, fish oils (mainly cod liver oil), plant oils (largely evening primrose oil), minerals and glucosamine supplement products.
The functional foods sector increased by 8.3% in value terms in the year ending 8th September 2007, a substantial slowing of growth from the 22.1% rise shown in the year to 9th September 2006. This slowdown was accounted for by a decline in sales of probiotic yoghurt drinks (which appear to have peaked after strong previous growth), while sales of cholesterol-lowering margarines and spreads experienced only a slight rise. However, some positive growth was achieved through increased sales of fortified breakfast cereals, probiotic yoghurts and soya milks.
To read more of this press release from PR-inside.com, click here.
and minerals; probiotic yoghurts and yoghurt drinks; cholesterol-lowering margarines; and soya milks. A newer and growing segment is fortified breads. Fortified breakfast cereals and probiotic yoghurts/yoghurt drinks are claimed to aid digestion, and cholesterol-lowering margarines are targeted at heart health. The use of the cholesterol-lowering active ingredients has been extended to probiotic yoghurts and yoghurt drinks, and to milk and cheese.
The smaller VMS sector is dominated by single and multivitamins, fish oils (mainly cod liver oil), plant oils (largely evening primrose oil), minerals and glucosamine supplement products.
The functional foods sector increased by 8.3% in value terms in the year ending 8th September 2007, a substantial slowing of growth from the 22.1% rise shown in the year to 9th September 2006. This slowdown was accounted for by a decline in sales of probiotic yoghurt drinks (which appear to have peaked after strong previous growth), while sales of cholesterol-lowering margarines and spreads experienced only a slight rise. However, some positive growth was achieved through increased sales of fortified breakfast cereals, probiotic yoghurts and soya milks.
To read more of this press release from PR-inside.com, click here.
Press Release: CV Technologies Set for Growth Says CEO
EDMONTON, ALBERTA--(Marketwire - March 26, 2008) - CV Technologies Inc. (TSX:CVQ) - CV Technologies' recent financial and operational performance sets the stage for successful long-term growth through product line and geographic diversification, said President, CEO and Chief Scientific Officer Dr. Jacqueline Shan, speaking today to the Company's Annual General Meeting of shareholders at the Alberta Research Council in Edmonton.
"Our road map is predicated on our belief that CV Technologies will continue as a leader in our product category in Canada, and that we will extend the COLD-fX® line and introduce other new products," Dr. Shan said. She observed that "Canada will remain our engine, serving as a showcase for our products and generating the financial and other resources that we expect will ultimately permit us to thrive in the global market".
"Our initial investment of money and time in establishing U.S. relationships continues to demonstrate benefits. We have maintained favorable profiles with respected U.S. opinion leaders in the scientific, regulatory, medical and journalistic communities. And we are confident their goodwill will translate into support for future efforts, when the time is right," she said.
"Recently, the U.S. Food and Drug Administration approved the first botanical drug product. We are exploring the possibility of obtaining U.S. botanical drug registration for COLD-fX, which would allow us to make therapeutic claims," Dr. Shan remarked. "In addition, we are in early stage discussions with potential strategic partners about the prospects for developing new products and extensions to our existing lines for global distribution. We are also exploring licensing our intellectual property for use in industries like functional foods and animal supplements."
To read more of this press release from MarketWire, click here.
"Our road map is predicated on our belief that CV Technologies will continue as a leader in our product category in Canada, and that we will extend the COLD-fX® line and introduce other new products," Dr. Shan said. She observed that "Canada will remain our engine, serving as a showcase for our products and generating the financial and other resources that we expect will ultimately permit us to thrive in the global market".
"Our initial investment of money and time in establishing U.S. relationships continues to demonstrate benefits. We have maintained favorable profiles with respected U.S. opinion leaders in the scientific, regulatory, medical and journalistic communities. And we are confident their goodwill will translate into support for future efforts, when the time is right," she said.
"Recently, the U.S. Food and Drug Administration approved the first botanical drug product. We are exploring the possibility of obtaining U.S. botanical drug registration for COLD-fX, which would allow us to make therapeutic claims," Dr. Shan remarked. "In addition, we are in early stage discussions with potential strategic partners about the prospects for developing new products and extensions to our existing lines for global distribution. We are also exploring licensing our intellectual property for use in industries like functional foods and animal supplements."
To read more of this press release from MarketWire, click here.
Subscribe to:
Posts (Atom)
